Loading...
XPAR
VETO
Market cap1.09bUSD
Sep 22, Last price  
77.30EUR
1D
0.00%
1Q
12.00%
Jan 2017
72.19%
IPO
240.87%
Name

Vétoquinol

Chart & Performance

D1W1MN
P/E
15.54
P/S
1.69
EPS
4.97
Div Yield, %
1.08%
Shrs. gr., 5y
-0.06%
Rev. gr., 5y
6.37%
Revenues
539m
+1.88%
196,617,000211,591,000233,364,000234,395,000257,057,000282,041,000284,137,000298,293,000299,727,000315,298,000342,612,000350,354,000352,173,000367,941,000395,990,000427,467,000521,272,000539,779,000529,270,999539,196,000
Net income
59m
+5.62%
12,440,72015,824,00018,642,00018,564,00018,207,00022,255,00022,695,00022,569,00023,580,00025,766,00024,156,00027,827,00034,831,00036,259,00028,589,00019,221,00062,861,00047,995,00055,560,00058,685,000
CFO
86m
-3.99%
30,014,00023,356,00037,215,00021,903,00040,046,00034,360,00029,992,00034,209,00028,106,00041,298,00038,897,00043,205,00041,225,00037,884,00052,024,00092,012,00089,167,00062,392,00089,391,00085,826,000
Dividend
Jun 04, 20240.85 EUR/sh

Profile

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
URL
https://www.vetoquinol.com/fr
IPO date
Nov 16, 2006
Employees
2,455
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
539,196
1.88%
529,271
-1.95%
539,779
3.55%
Cost of revenue
256,314
460,546
487,931
Unusual Expense (Income)
NOPBT
282,882
68,725
51,848
NOPBT Margin
52.46%
12.98%
9.61%
Operating Taxes
22,332
21,340
20,649
Tax Rate
7.89%
31.05%
39.83%
NOPAT
260,550
47,385
31,199
Net income
58,685
5.62%
55,560
15.76%
47,995
-23.65%
Dividends
(10,058)
(9,465)
(9,465)
Dividend yield
1.14%
0.78%
0.91%
Proceeds from repurchase of equity
(2,934)
BB yield
0.33%
Debt
Debt current
9,908
7,965
7,860
Long-term debt
27,768
24,132
9,561
Deferred revenue
9,382
Other long-term liabilities
9,418
8,901
9,220
Net debt
(168,655)
(116,858)
(77,731)
Cash flow
Cash from operating activities
85,826
89,391
62,392
CAPEX
(14,545)
(14,896)
(22,497)
Cash from investing activities
(15,647)
(18,881)
(21,518)
Cash from financing activities
(16,028)
(15,497)
(15,600)
FCF
257,583
(2,705)
(6,598)
Balance
Cash
206,331
147,464
93,708
Long term investments
1,491
1,444
Excess cash
179,371
122,491
68,163
Stockholders' equity
88,482
485,984
491,532
Invested Capital
517,991
431,148
437,563
ROIC
54.90%
10.91%
7.31%
ROCE
46.18%
12.25%
10.09%
EV
Common stock shares outstanding
11,796
11,833
11,832
Price
74.90
-26.86%
102.40
16.89%
87.60
-33.64%
Market cap
883,496
-27.08%
1,211,649
16.90%
1,036,447
-33.61%
EV
714,933
1,094,888
958,808
EBITDA
313,500
103,227
83,398
EV/EBITDA
2.28
10.61
11.50
Interest
1,236
1,137
3,261
Interest/NOPBT
0.44%
1.65%
6.29%